ProQR Therapeutics N.V. - ROE
PRQR
Price:
$1.89
Market Cap:
$173.54M
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strateg...[Read more]
Industry
Biotechnology
IPO Date
2014-09-18
Stock Exchange
NASDAQ
Ticker
PRQR
PE Ratio
[-3.78]
ROE
[-86.47%]
Current Ratio
[2.48]
Dividend Yield
[0%]
Enterprise Value
[106.06M]
Dividend History
The ROE as of June 2026 (TTM) for ProQR Therapeutics N.V. (PRQR) is -86.47%
According to ProQR Therapeutics N.V.’s latest financial reports and current stock price. The company's current ROE is -86.47%. This represents a change of 277.97% compared to the average of -22.88% of the last 4 quarters.
ProQR Therapeutics N.V. (PRQR) Historical ROE (quarterly & annually)
How has PRQR ROE performed in the past?
The mean historical ROE of ProQR Therapeutics N.V. over the last ten years is -66.88%. The current -86.47% ROE has changed 29.30% with respect to the historical average. Over the past ten years (40 quarters), PRQR's ROE was at its highest in in the June 2020 quarter at -5.13%. The ROE was at its lowest in in the March 2026 quarter at -36.14%.
Average
-66.88%
Median
-64.08%
Minimum
-110.86%
Maximum
-31.35%
ProQR Therapeutics N.V. (PRQR) ROE by Quarter and Year
Discovering the peaks and valleys of ProQR Therapeutics N.V. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 217.22%
Maximum Annual ROE = -31.35%
Minimum Annual Increase = -64.18%
Minimum Annual ROE = -110.86%
| Year | ROE | Change |
|---|---|---|
| 2025 | -82.10% | 161.89% |
| 2024 | -31.35% | -49.03% |
| 2023 | -61.50% | -35.98% |
| 2022 | -96.06% | 80.03% |
| 2021 | -53.36% | -19.95% |
| 2020 | -66.66% | 24.38% |
| 2019 | -53.59% | 34.97% |
| 2018 | -39.71% | -64.18% |
| 2017 | -110.86% | 50.64% |
| 2016 | -73.59% | 217.22% |
ProQR Therapeutics N.V. (PRQR) Average ROE
How has PRQR ROE performed in the past?
The current ROE of ProQR Therapeutics N.V. (PRQR) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-58.32%
5-year avg
-64.87%
10-year avg
-66.88%
ProQR Therapeutics N.V. (PRQR) ROE vs. Peers
How is PRQR’s ROE compared to its peers?
ProQR Therapeutics N.V.’s ROE is greater than Immutep Limited (-69.20%), greater than Editas Medicine, Inc. (-677.39%), greater than Capricor Therapeutics, Inc. (-59.27%), greater than Achieve Life Sciences, Inc. (-193.49%), greater than Allogene Therapeutics, Inc. (-56.45%), greater than Arcturus Therapeutics Holdings Inc. (-36.55%), greater than Mereo BioPharma Group plc (-81.25%), greater than Vanda Pharmaceuticals Inc. (-61.41%), greater than Entrada Therapeutics, Inc. (-51.22%), greater than Zura Bio Limited (-54.60%),
| Company | ROE | Market cap |
|---|---|---|
| -69.20% | $55.15M | |
| -677.39% | $263.35M | |
| -59.27% | $1.30B | |
| -193.49% | $497.90M | |
| -56.45% | $487.74M | |
| -36.55% | $214.03M | |
| -81.25% | $49.39M | |
| -61.41% | $348.79M | |
| -51.22% | $275.24M | |
| -54.60% | $243.83M |
Build a custom stock screener for ProQR Therapeutics N.V. (PRQR) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ProQR Therapeutics N.V. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
ProQR Therapeutics N.V. (PRQR) and other stocks custom spreadsheet templates
The easiest way to analyze a company like ProQR Therapeutics N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is ProQR Therapeutics N.V.'s ROE?
How is the ROE calculated for ProQR Therapeutics N.V. (PRQR)?
What is the highest ROE for ProQR Therapeutics N.V. (PRQR)?
What is the 3-year average ROE for ProQR Therapeutics N.V. (PRQR)?
What is the 5-year average ROE for ProQR Therapeutics N.V. (PRQR)?
How does the current ROE for ProQR Therapeutics N.V. (PRQR) compare to its historical average?